Prolonged post-ablation fever may predict one-year tumor recurrence in hepatocellular carcinoma after radiofrequency ablation

References

• M.D. Augusto Villanueva. Hepatocellular carcinoma. N Engl J Med. 2019;381(1):e2.
   PubMedGoogle Scholar
• Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013;59(2):300–307.
   PubMed Web of Science ®Google Scholar
• Hung HH, Chiou YY, Hsia CY, et al. Survival rates are comparable after radiofrequency ablation or surgery in patients with small hepatocellular carcinomas. Clin Gastroenterol Hepatol. 2011;9(1):79–86.
   PubMed Web of Science ®Google Scholar
• Wang J-H, Wang C-C, Hung C-H, et al. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol. 2012;56(2):412–418.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Lin C-J, Lin C-C, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma≤ 4 cm. Gastroenterology. 2004;127(6):1714–1723.
   PubMed Web of Science ®Google Scholar
• Wah TM, Arellano RS, Gervais DA, et al. Image-guided percutaneous radiofrequency ablation and incidence of post–radiofrequency ablation syndrome: prospective survey. Radiology. 2005;237(3):1097–1102.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al.; Standard of Practice Committee of the Cardiovascular and Interventional Radiological Society of Europe. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241–260.
   PubMed Web of Science ®Google Scholar
• Peng C-W, Teng W, Hsieh Y-C, et al. Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Adv Dig Med. 7:83–92.
   Web of Science ®Google Scholar
• Liver EAFTSOT. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Kondo Y, Yoshida H, Shiina S, et al. Artificial ascites technique for percutaneous radiofrequency ablation of liver cancer adjacent to the gastrointestinal tract. Br J Surg. 2006;93(10):1277–1282.
   PubMed Web of Science ®Google Scholar
• Luo W, Zhang Y, He G, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis. World J Surg Onc. 2017;15(1):126.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–060. © Thieme Medical Publishers,
   Google Scholar
• Teng W, Liu K-W, Lin C-C, et al. Insufficient ablative margin determined by early computed tomography may predict the recurrence of hepatocellular carcinoma after radiofrequency ablation. Liver Cancer. 2015;4(1):26–38.
   PubMed Web of Science ®Google Scholar
• Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98(1):119–127.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474.
   PubMed Web of Science ®Google Scholar
• Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Lissen E, Clumeck N, APRICOT Clinical Investigators, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325.
   PubMed Web of Science ®Google Scholar
• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–558.
   PubMed Web of Science ®Google Scholar
• Edmondson HA, Steiner PE. Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer. 1954;7(3):462–503.
   PubMed Web of Science ®Google Scholar
• Han T-S, Ban HS, Hur K, et al. The epigenetic regulation of HCC metastasis. IJMS. 2018;19(12):3978.
   Google Scholar
• Lee SH, Kim SU, Jang JW, et al. Use of transient elastography to predict de novo recurrence after radiofrequency ablation for hepatocellular carcinoma. OncoTargets Ther. 2015;8:347.
   PubMed Web of Science ®Google Scholar
• Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019;70(5):866–873.
   PubMed Web of Science ®Google Scholar
• Park JG, Park SY, Tak WY, et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol. 2017;72(8):692.e9-692–e15.
   Web of Science ®Google Scholar
• Rhim H. Complications of radiofrequency ablation in hepatocellular carcinoma. Abdom Imaging. 2005;30(4):409–418.
   PubMedGoogle Scholar
• Livraghi T, Solbiati L, Meloni MF, et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–451.
   PubMed Web of Science ®Google Scholar
• Rhim H, Yoon KH, Lee JM, et al. Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings. Radiographics. 2003;23(1):123–134.
   PubMed Web of Science ®Google Scholar
• Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol. 2001;12(3):313–320.
   PubMed Web of Science ®Google Scholar
• Choi JB, Rhim HC, Kim YS, et al. Radiofrequency thermal ablation of malignant hepatic tumors: post-ablation syndrome. J Korean Radiol Soc. 2000;43(1):63–68.
   Google Scholar
• Nault JC, Sutter O, Nahon P, et al. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. J Hepatol. 2018;68(4):783–797.
   PubMed Web of Science ®Google Scholar
• Lee MW, Kang D, Lim HK, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma< 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020;30:2391–2400.
   PubMed Web of Science ®Google Scholar
• Canale M, Ulivi P, Foschi FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. Crit RevOncol/Hematol. 2018;129:44–53.
   PubMed Web of Science ®Google Scholar
• Hansler J, Wissniowski TT, Schuppan D, et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006;12(23):3716–3721.
   PubMed Web of Science ®Google Scholar
• Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138(5):1931–1942.
   PubMed Web of Science ®Google Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017;66(3):545–551.
   PubMed Web of Science ®Google Scholar
• Sanghera C, Teh JJ, Pinato DJ. The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019;39(11):2008–2023.
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–1655.
   PubMed Web of Science ®Google Scholar